Press Releases
Alzheon Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801 Oral Tablet in APOE4 Carriers with Alzheimer’s Disease
Study Evaluates Biomarker Evidence of Disease Modification in APOE4 Carriers, Who Comprise Two-Thirds of All Alzheimer’s Patients
Peer-Reviewed Scientific Publication Demonstrates Central Role of Neurotoxic Soluble Amyloid Oligomers in Driving Alzheimer’s Pathogenesis
Inhibition of Amyloid Toxicity Represents the Only Clinically Validated Approach for Slowing Progression of Alzheimer’s Disease
Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ 801 in Patients with Early Alzheimer’s Disease
Study to Confirm ALZ-801 Effects on Cognition and Function in High-Risk Patients with APOE4/4 Genotype
Alzheon Partners with Czech Institute of Organic Chemistry and Biochemistry to Develop First Alzheimer’s Diagnostic Assay for Measuring Neurotoxic Beta Amyloid Oligomers in Human Brain
Assay Builds on Alzheon’s Research to Detect and Quantify Soluble Oligomers, and Enhances Phase 2 and Phase 3 Alzheimer’s Studies with Oral ALZ-801.
Alzheon to Present at H.C. Wainwright Global Life Sciences Conference
Dr. Martin Tolar, CEO of Alzheon will Present an Overview of Oral Anti-amyloid ALZ-801 Phase 3 Program at the H.C. Wainwright Global Life Sciences Virtual Conference.
Alzheon CEO Presents Overview of Oral Anti-Amyloid ALZ-801 Phase 3 Program at 9th Neurodegenerative Drug Development Summit
Dr. Martin Tolar to Provide an Update on Alzheon’s ALZ-801 Phase 3 Program and Join Panel Discussion on Current Research in Alzheimer’s Disease.